Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Call Transcript & Summary

June 30, 2020

NASDAQ US Health Care Biotechnology shareholder_meeting 7 min

Earnings Call Speaker Segments

Thomas Beetham

executive
#1

At the top of the hour, it's 8 a.m. Eastern Time, 9 a.m. Atlantic time, we're going to get started. Welcome to the 2020 Annual Meeting of Kiniksa Pharmaceuticals Limited. My name is Tom Beetham. I'm the Chief Legal Officer and Secretary of the company. A quorum is present, and I declare this meeting to be open. Before I turn the meeting over to the Chairman of the Board, there are a few procedural matters that I'd like to review. The notice of the meeting was distributed on or about April 28, 2020, to all shareholders of record entitled to vote at this meeting as of the close of business on the record date of April 22. We refer to these shareholders during this meeting as our record holders. In coordination with Broadridge Financial Solutions, Jenna Bentley of Borden Consulting Group has been appointed to serve as inspector of elections for this meeting. Jenna will be supervising the counting and tabulating of all the votes. If you have already submitted a proxy, you will not need to vote during the meeting since your proxy will be voted as directed. However, if for any reason, you wish to vote during the meeting, while the polls for voting are open, you may do that at the bottom panel of your screen in the web portal. As a preliminary matter, the Bermuda Companies Act requires that the company's audited financial statements for the year ended December 31, 2019, and the auditor's report be presented for review at this meeting. A copy of the company's proxy statement for this meeting and the company's annual report to shareholders, which includes the company's audited financial statements and auditor's report for the fiscal year 2019 were distributed to our record holders on April 28, 2020. These materials are available for review at this meeting at the bottom panel of your screen in the web portal. About questions. Today, we'll be taking questions only on the proposals for consideration at this meeting, and we'll do that after we describe each proposal. With respect to questions on any other matters, we request that you contact us following the meeting with your questions by e-mailing our Investor Relations department using the e-mail address of [email protected]. Now I'm pleased to introduce the company's Chief Executive Officer and Chairman of the Board of Directors, Sanj K. Patel. Sanj?

Sanj Patel

executive
#2

Thank you, Tom. On behalf of myself and the Board, I extend a warm welcome to our shareholders present today at the 2020 Annual General Meeting of the company. We will now turn to the business of this meeting. As described in our proxy statement for this meeting, there are 2 proposals for consideration. We will take each proposal in turn and provide an opportunity to ask questions on the proposal. The first proposal is to elect Stephen Biggar and Barry Quart as Class II directors to serve until the 2023 Annual Meeting of Shareholders and until their respective successors shall have been duly elected and qualified. [Operator Instructions]

Thomas Beetham

executive
#3

We will pause now for a few moments to see if there are any questions that come in. As there are no questions, we will now proceed to the second proposal. Sanj?

Sanj Patel

executive
#4

Thanks, Tom. The second proposal is to approve the appointment of PricewaterhouseCoopers LLP as the company's statutory auditors until the close of the company's next Annual Meeting of Shareholders. To approve the delegation to our Board through its audit committee of the authority to set the auditors' remuneration for such period and to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2020. [Operator Instructions]

Thomas Beetham

executive
#5

We will pause now for a few moments to see if there are any questions. As there are no questions, we will now proceed to the voting procedures. We'll now proceed to open the polls for voting. Again, if you have already submitted a proxy, you will not need to vote during the meeting since your proxy will be voted as directed. However, for any reason you wish to vote during the meeting, while the polls are now open, you may do so at the bottom panel of your screen in the web portal. We'll pause now for a few moments to see if there are any additional votes. [Voting]

Thomas Beetham

executive
#6

Okay. We will now close the polls for voting. The polls are now closed. I will now report the preliminary results of voting. The inspector of elections has informed us that the preliminary vote report indicates that proposal 1 to elect each nominee to serve as a Class II Director has passed and proposal 2 to appoint PricewaterhouseCoopers LLP as the company's statutory auditors, delegate authority to set the remuneration of such auditors and ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered accounting firm has passed. Sanj?

Sanj Patel

executive
#7

Thanks, Tom. As there is no further business to properly brought to this meeting, I declare the 2020 Annual General Meeting of the company to be adjourned. Thank you for attending.

Operator

operator
#8

This conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

For developers and AI pipelines

Programmatic access to Kiniksa Pharmaceuticals International, plc earnings transcripts and 32,000+ others is available through the EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.